High Fecal Prevalence of mcr-Positive Escherichia coli in Veal Calves at Slaughter in France
- PMID: 36009940
- PMCID: PMC9405437
- DOI: 10.3390/antibiotics11081071
High Fecal Prevalence of mcr-Positive Escherichia coli in Veal Calves at Slaughter in France
Abstract
The aim of this study was to determine the percentage of healthy veal calves carrying mcr-positive E. coli strains at the time of slaughter in France. Fecal samples were selectively screened for mcr-positive E. coli isolates using media supplemented with colistin. Screening for mcr genes was also carried out in E. coli isolates resistant to critically important antimicrobials used in human medicine recovered from the same fecal samples. Overall, 28 (16.5%) out of the 170 veal calves tested carried mcr-positive E. coli. As some calves carried several non-redundant mcr-positive strains, 41 mcr-positive E. coli were recovered. Thirty-one and seven strains were positive for mcr-1 and mcr-3 genes, respectively, while no strain was positive for the mcr-2 gene. Co-carriage of mcr-1 and mcr-3 was identified in three strains. All mcr-positive E. coli isolates, except one, were multidrug-resistant, with 56.1% being ciprofloxacin-resistant and 31.7% harboring blaCTX-M genes. All mcr-3-positive E. coli carried blaCTX-M genes, mainly blaCTX-M-55. This study highlights the high prevalence of mcr-positive E. coli strains in feces of veal calves at the time of slaughter. It also points out the multidrug (including ciprofloxacin) resistance of such strains and the co-occurrence of mcr-3 genes with blaCTX-M-55 genes.
Keywords: Escherichia coli; colistin; critically important antibiotics; extended spectrum β-lactamase; healthy veal calves; mcr genes.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Nation R.L., Li J., Cars O., Couet W., Dudley M.N., Kaye K.S., Mouton J.W., Paterson D.L., Tam V.H., Theuretzbacher U., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect. Dis. 2015;15:225–234. doi: 10.1016/S1473-3099(14)70850-3. - DOI - PubMed
-
- Catry B., Cavaleri M., Baptiste K., Grave K., Grein K., Holm A., Jukes H., Liebana E., Navas A.L., Mackay D., et al. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): Development of resistance in animals and possible impact on human and animal health. Int. J. Antimicrob. Agents. 2015;46:297–306. doi: 10.1016/j.ijantimicag.2015.06.005. - DOI - PubMed
-
- Liu Y.-Y., Wang Y., Walsh T.R., Yi L.-X., Zhang R., Spencer J., Doi Y., Tian G., Dong B., Huang X., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect. Dis. 2016;16:161–168. doi: 10.1016/S1473-3099(15)00424-7. - DOI - PubMed
-
- Xavier B.B., Lammens C., Ruhal R., Kumar-Singh S., Butaye P., Goossens H., Malhotra-Kumar S. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Eurosurveillance. 2016;21:30280. doi: 10.2807/1560-7917.ES.2016.21.27.30280. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
